Why Quantum BioPharma Ltd.’s (QNTM) Stock Is Up 8.01%
As of Tuesday, May 26, Quantum BioPharma Ltd.’s QNTM share price has surged by 8.01%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Jenna Brashear
Jenna Brashear
Jenna Brashear
| Share Statistics | QNTM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $18.5 | $579.1 | 10% |
|
| Shares Out (Mil) | 4.5 | 43.0 | 13% |
|
| Institutional Ownership | 62.8% | 84.3% | 40% |
|
| Float (Mil) | 6.0 | 46.8 | 14% |
|
| Beta | 0.36 | 0.62 | 20% |
|
| Avg Daily Volume (000s) | 90 | 285 | 35% |
|
| Price Change (52-week) |
(87.2%) | 63.8% | 5% |
|
| Growth | QNTM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | 3.8% | (1.4%) | 45% |
|
| EPS (5yr) | 45.9% | 14.9% | 91 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.1%) | (14.9%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | QNTM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $272 | na |
|
| Net Income (TTM) (Mil) | ($31) | ($11) | 20% |
|
| EPS (TTM) | ($8.222) | ($0.500) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($6) | 24% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $4 | 46% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | $38 | $522 | 15% |
|
| Valuation | QNTM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 29.10 | 2.73 | 97% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | QNTM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (209.1%) | (24.6%) | 2% |
|
| ROE | (984.8%) | (19.7%) | 0% |
|
| Liabilities to Assets | 109.5% | 35.5% | 95% |
|
| F-Score | 1 | 3 | 1% |
|
Quantum BioPharma Ltd. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors